Analysts expect MEDNAX, Inc. (NYSE:MD) to report $0.42 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for MEDNAX’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.38. MEDNAX posted earnings of $0.37 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.5%. The company is scheduled to issue its next quarterly earnings results on Friday, November 5th.
On average, analysts expect that MEDNAX will report full-year earnings of $1.46 per share for the current financial year, with EPS estimates ranging from $1.38 to $1.54. For the next fiscal year, analysts anticipate that the firm will report earnings of $1.75 per share, with EPS estimates ranging from $1.71 to $1.85. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover MEDNAX.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Friday, August 6th. The company reported $0.41 EPS for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.09. The company had revenue of $473.00 million during the quarter, compared to analyst estimates of $453.12 million. MEDNAX had a negative net margin of 2.93% and a positive return on equity of 12.13%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.32 EPS.
In other news, insider Roger Mack Hinson sold 8,799 shares of the business’s stock in a transaction that occurred on Tuesday, August 10th. The shares were sold at an average price of $32.35, for a total value of $284,647.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark S. Ordan sold 95,000 shares of the stock in a transaction dated Monday, August 30th. The stock was sold at an average price of $35.09, for a total transaction of $3,333,550.00. The disclosure for this sale can be found here. Insiders own 2.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its holdings in MEDNAX by 5.6% in the 1st quarter. BlackRock Inc. now owns 13,377,791 shares of the company’s stock worth $340,731,000 after purchasing an additional 705,924 shares during the period. Vanguard Group Inc. raised its position in MEDNAX by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 9,214,541 shares of the company’s stock valued at $277,819,000 after purchasing an additional 212,757 shares in the last quarter. Earnest Partners LLC raised its position in MEDNAX by 19.4% in the 1st quarter. Earnest Partners LLC now owns 7,086,303 shares of the company’s stock valued at $180,488,000 after purchasing an additional 1,149,651 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in MEDNAX by 3.9% in the second quarter. Alliancebernstein L.P. now owns 6,728,916 shares of the company’s stock valued at $202,877,000 after purchasing an additional 254,015 shares in the last quarter. Finally, FMR LLC raised its holdings in MEDNAX by 13.7% during the second quarter. FMR LLC now owns 4,886,336 shares of the company’s stock worth $147,323,000 after purchasing an additional 588,474 shares in the last quarter.
Shares of MD traded up $0.03 during mid-day trading on Tuesday, reaching $28.80. 17,082 shares of the company’s stock traded hands, compared to its average volume of 741,895. The stock’s 50-day moving average is $30.90 and its two-hundred day moving average is $29.69. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.14 and a quick ratio of 2.14. The stock has a market cap of $2.49 billion, a P/E ratio of -45.71, a P/E/G ratio of 1.15 and a beta of 2.18. MEDNAX has a 12 month low of $12.47 and a 12 month high of $35.67.
MEDNAX Company Profile
MEDNAX, Inc provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.
Recommended Story: Price Target
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.